In SilicoApproach towards Designing Virtual Oligopeptides for HRSV

HRSV (human respiratory syncytial virus) is a serious cause of lower respiratory tract illness in infants and young children. Designing inhibitors from the proteins involved in virus replication and infection process provides target for new therapeutic treatments. In the present study,in silicodocking was performed using motavizumab as a template to design motavizumab derived oligopeptides for developing novel anti-HRSV agents. Additional simulations were conducted to study the conformational propensities of the oligopeptides and confirmed the hypothesis that the designed oligopeptide is highly flexible and capable of assuming stable confirmation. Our study demonstrated the best specific interaction of GEKKLVEAPKS oligopeptide for glycoprotein strain A among various screened oligopeptides. Encouraged by the results, we expect that the proposed scheme will provide rational choices for antibody reengineering which is useful for systematically identifying the possible ways to improve efficacy of existing antibody drugs.

Download Full-text

Lack of Usefulness of an Abnormal White Blood Cell Count for Predicting a Concurrent Serious Bacterial Infection in Infants and Young Children Hospitalized With Respiratory Syncytial Virus Lower Respiratory Tract Infection

The Pediatric Infectious Disease Journal ◽

10.1097/01.inf.0000258627.23337.00 ◽

2007 ◽

Vol 26 (4) ◽

pp. 311-315 ◽

Cited By ~ 29

Author(s):

Kevin Purcell ◽

Jaime Fergie

Keyword(s):

Respiratory Syncytial Virus ◽

Tract Infection ◽

Respiratory Tract ◽

Blood Cell ◽

Bacterial Infection ◽

Cell Count ◽

Lower Respiratory Tract ◽

Blood Cell Count ◽

Syncytial Virus ◽

Infants And Young Children

Download Full-text

B11/349 – Risk factors associated with severe Respiratory Syncytial Virus (RSV)-induced Lower Respiratory Tract Infection (LRTI) in infants and young children over four consecutive seasonal epidemics in Italy

Paediatric Respiratory Reviews ◽

10.1016/j.prrv.2006.04.070 ◽

2006 ◽

Vol 7 ◽

pp. S295

Author(s):

G.A. Rossi ◽

R. Merolla ◽

Paparatti U. Di Luzio ◽

M. Silvestri ◽

C. Chezzi ◽

...

Keyword(s):

Risk Factors ◽

Respiratory Syncytial Virus ◽

Tract Infection ◽

Respiratory Tract ◽

Lower Respiratory Tract ◽

Severe Respiratory Syncytial Virus ◽

Factors Associated ◽

Seasonal Epidemics ◽

Syncytial Virus ◽

Infants And Young Children

Download Full-text

Serious Early Childhood Wheezing After Respiratory Syncytial Virus Lower Respiratory Tract Illness in Preterm Infants

Clinical Therapeutics ◽

10.1016/j.clinthera.2011.01.007 ◽

2010 ◽

Vol 32 (14) ◽

pp. 2422-2432 ◽

Cited By ~ 11

Author(s):

José R. Romero ◽

Dan L. Stewart ◽

Erin K. Buysman ◽

Ancilla W. Fernandes ◽

Hasan S. Jafri ◽

...

Keyword(s):

Early Childhood ◽

Respiratory Syncytial Virus ◽

Respiratory Tract ◽

Preterm Infants ◽

Lower Respiratory Tract ◽

Respiratory Tract Illness ◽

Syncytial Virus

Download Full-text

Infection by the respiratory syncytial virus in infants and young children at high risk

Cardiology in the Young ◽

10.1017/s1047951105000545 ◽

2005 ◽

Vol 15 (3) ◽

pp. 256-265 ◽

Cited By ~ 13

Author(s):

Damien Bonnet ◽

Achim A. Schmaltz ◽

Timothy F. Feltes

Keyword(s):

Respiratory Syncytial Virus ◽

High Risk ◽

Respiratory Tract ◽

Lung Disease ◽

Chronic Lung Disease ◽

Lower Respiratory Tract ◽

First Year ◽

Syncytial Virus ◽

First Year Of Life ◽

Infants And Young Children

The respiratory syncytial virus is the most common cause of infection of the lower respiratory tract in infants and young children, and is the leading cause of hospitalisation and death due to viral illness during the first year of life. In otherwise healthy infants, the virus usually causes only mild respiratory illness, but premature babies and infants with chronic lung disease, those with congenitally malformed hearts, or those who are immunodeficient, are at increased risk of serious illness, hospitalisation, and death. Recent infection with the virus is also associated with increased postoperative complications after corrective surgery for congenitally malformed hearts. No effective vaccine is currently available, and treatment is limited to supportive therapy. Prevention in groups deemed to be at high-risk, therefore, is essential. In addition to measures for control of infection, prophylactic immunotherapy is indicated in selected patients. Palivizumab (Synagis®) is a monoclonal antibody indicated for the prevention of serious viral disease of the lower respiratory tract in premature infants, those with chronic lung disease, and those with haemodynamically significant congenital cardiac lesions. Palivizumab is given intramuscularly, usually as a monthly injection during the so-called “season”. In a recent international, randomised, double-blind, placebo-controlled trial in 1,287 children less than or equal to 2 years old with haemodynamically significant congenital cardiac malformations, prophylaxis achieved a relative reduction of 45 per cent in the incidence of antigen-confirmed viral-related hospitalisation, and reduced the duration of hospital stay by 56 per cent. National and international guidelines, therefore, now recommend routine prophylaxis in the first year of life in children with haemodynamically significant congenital cardiac disease.

Download Full-text